Implementing ctDNA and Circular DNA in Patients With Localized Pancreatic Cancer

Recruiting now · Not applicable

Conditions studied: Resectable Pancreatic Cancer

In brief

The goal of this clinical trial is to investigate if plasma ctDNA and eccDNA before resection for suspicion of pancreatic ductal adenocarcinoma (PDAC) can predict early recurrence and overall survival, and to investigate if plasma ctDNA combined with CT scan and endoscopic ultrasound surveillance increases the median overall survival compared with standard-of-care surveillance.

Key facts

Study ID: NCT05788744
Run by: Copenhagen University Hospital at Herlev
People needed: 1000
Starts: 2023-01-01
Expected to finish: 2032-01-01
Last updated by the study team: 2026-03-27

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Sub-study 1: Suspicion of PDAC tumor stage I-III, scheduled for pancreatic resection, with or without preoperative neoadjuvant chemotherapy.
Sub-study 2: .
PDAC tumor stage I-III
Has received intended curative resection (R0/R1) of PDAC
No signs of local recurrence or metastatic disease at a CT scan 4 months after the operation

You may not qualify if…

Other cancers (excluding skin cancer other than melanoma) later than 3 years before inclusion
Patients who are unlikely to comply with the protocol, inability to return for subsequent visits) and/or otherwise considered by the Investigator to be unlikely to complete the study

Where it is running

Aalborg Universitetshospital — Aalborg, Denmark (enrolling)
Aarhus Universitetshospital — Aarhus, Denmark (enrolling)
Copenhagen University Hospital - Rigshospitalet — Copenhagen, Denmark (enrolling)
Copenhagen University Hospital - Herlev and Gentofte — Herlev, Denmark (enrolling)
Odense Universitetshospital — Odense, Denmark (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.